Cantargia publishes prospectus in connection with the list change to Nasdaq Stockholm’s main market
On 13 September 2018, Cantargia AB (publ) (“Cantargia” or the ”Company”) announced that Nasdaq Stockholm’s Listing Committee had approved the admission of the Company’s shares for trading on Nasdaq Stockholm’s regulated market.
The Swedish prospectus that has been prepared in connection with the list change is now held available on Cantargia’s website, www.cantargia.com, and can also be ordered by telephone +46 (0)46-275 62 60.
First day of trading on the main market is 25 September 2018. Last day of trading on Nasdaq First North Premier is 24 September 2018. Shareholders in the Company are not required to take any actions in connection with the list change.
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com
About Cantargia
Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life-threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein (IL1RAP) in leukemic stem cells. Subsequent research has also identified IL1RAP in many other forms of cancer. The company’s main project, the CAN04 (nidanilimab) antibody targeted against IL1RAP, is being studied in the CANFOUR clinical phase I/IIa study, where the primary focus is on non-small cell lung cancer and pancreatic cancer. CAN04 (nidanilimab) has two modes of action: it blocks the function of IL1RAP and stimulates the immune system to destroy tumour cells. Cantargia’s second project, currently in the research phase, is aimed at developing an IL1RAP-binding antibody that is optimised for treatment of autoimmune and inflammatory diseases.
Cantargia is listed on Nasdaq Stockholm First North Premier (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.